Screening blood donations for human T-lymphotropic virus types I and II (HTLV-I/II) continues to be important in protecting the safety of blood products and controlling the global spread of these retroviruses. We have developed a fully automated, third generation chemiluminescent immunoassay, ARCHITECT rHTLV-I/II, for detection of antibodies to HTLV-I/II. The assay utilizes recombinant proteins and synthetic peptides and is configured in a double antigen sandwich assay format. Specificity of the assay was 99.98% (9,254/9,256, 95% CI = 99.92-100%) with the negative specimens from the general population including blood donors, hospital patients and pregnant women from the US, Japan and Nicaragua. The assay demonstrated 100% sensitivity by detecting 498 specimens from individuals infected with HTLV-I (n = 385) and HTLV-II (n = 113). ARCHITECT rHTLV-I/II results were in complete agreement with the Murex HTLV-I/II reference assay and 99.7% agreement with the Genelabs HTLV Blot 2.4 confirmatory assay. Analytical sensitivity of the assay was equivalent to Murex HTLV-I/II assay based on end point dilutions. Furthermore, using a panel of 397 specimens from Japan, the ARCHITECT rHTLV-I/II assay exhibited distinct discrimination between the antibody negative (Delta Value = -7.6) and positive (Delta Value = 7.6) populations. Based on the excellent specificity and sensitivity, the new ARCHITECT rHTLV-I/II assay should be an effective test for the diagnosis of HTLV-I/II infection and also for blood donor screening.
Background There have been a lot of studies on classification of Alzheimer’s disease (AD) based on its pathological process. These pathological changes have been defined by the ATN classification system (A : amyloid β (Aβ) deposition, T : pathogenic tau, N : neurodegeneration) based on cerebrospinal fluid (CSF) biomarker levels or neuroimaging. In order to promote research and practical application, it is necessary to develop a cost effective and minimally invasive technology. Therefore, we have developed plasma Aβ1‐40, Aβ1‐42, threonine‐181 phosphorylated tau (p‐tau181) and total‐tau immunoassay systems and reported that these plasma biomarkers levels were significantly different between AD and cognitively normal (CN). In this study we have measured biomarkers in other sample sets including mild cognitive impairment (MCI), and evaluated the performance in characterizing AD pathology, in the context of the ATN classification system. Method We measured commercially available plasma and CSF samples on the HISCLTM series, which can achieve high degrees of sensitivity and fast measurement times of 17 minutes, requiring only 10 to 30 µl of samples. The concentration of plasma and CSF biomarkers levels (Aβ1‐40, Aβ1‐42, p‐tau181, total‐tau) were measured and the significance of the difference between AD, MCI and CN groups was assessed. Result The AD group had lower Aβ1‐42/Aβ1‐40 ratio and higher levels of p‐tau181 and t‐tau compared to MCI or CN groups. The levels of plasma biomarkers in MCI group showed wide distribution compared to AD or CN group, suggesting these plasma biomarkers reflect the various pathological states of dementia in MCI patients. This might indicate that our plasma biomarker measurement systems represent characterization of AD pathological processes. Conclusion Our assay system revealed that the distribution of plasma biomarkers showed characteristic distribution in AD, MCI and CN groups, respectively. This result may indicate the possibility of practical diagnosis of AD pathology based on plasma biomarker ATN classification system. We aim to continue to measure other clinical sample sets for evaluation of the usefulness and universality of plasma biomarkers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.